Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy

Monoclonal antibody (mAb)-based blockade of programmed cell death 1 (PD-1) or its ligand to enable antitumor T-cell immunity has been successful in treating multiple tumors. However, the structural basis of the binding mechanisms of the mAbs and PD-1 and the effects of glycosylation of PD-1 on mAb i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hongchuan, Guo, Lijing, Zhang, Jing, Zhou, Yuehua, Zhou, Jinwei, Yao, Jian, Wu, Hai, Yao, Sheng, Chen, Bo, Chai, Yan, Qi, Jianxun, Gao, George F., Tan, Shuguang, Feng, Hui, Yan, Jinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601540/
https://www.ncbi.nlm.nih.gov/pubmed/30892132
http://dx.doi.org/10.1080/19420862.2019.1596513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601540/
https://www.ncbi.nlm.nih.gov/pubmed/30892132
http://dx.doi.org/10.1080/19420862.2019.1596513

Ejemplares similares